Effect of low-dose ATG on C-peptide production in new-onset type 1 diabetes
Effect of low-dose ATG on C-peptide production in new-onset type 1 diabetes
Predicted population mean of C-peptide AUC over time in placebo-treated and ATG-treated groups. Analysis at the 2-year endpoint p = 0.0005. Bars above and below the line indicate 95% CI.
ATG: anti-thymocyte globulin; AUC: area under the curve.
From: American Diabetes Association. Haller MJ, Long SA, Blanchfield JL, et al. Low-dose anti-thymocyte globulin preserves C-Peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: Two-year clinical trial data. Diabetes 2019; 68:1267. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.